TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2871239

Group type: EXPERIMENTAL
Intervention: Fetal phonogram measurement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fetal phonogram measurement during fetal breathing
Number of subjects: 12
Study: 29579957

Group type: EXPERIMENTAL
Intervention: Treatment 1 - received general information and information about the benefits (positive attributes)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Treatment 2 - received general information and information about the potential drawbacks (negative attributes)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group - received only general information
Number of subjects: 432
Study: 27094628

Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss (T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet-induced weight loss (D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise without weight loss (T-iD)
Number of subjects: 0
Study: 23680682

Group type: EXPERIMENTAL
Intervention: Mobilization within 24 hours of hospitalization
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mobilization between 24 to 48 hours after hospitalization
Number of subjects: 52
Study: 22723581

Group type: EXPERIMENTAL
Intervention: high-MUFA diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: high-MUFA diet plus physical activity program
Number of subjects: 45

Group type: COMPARATOR
Intervention: high-carbohydrate/high-fiber/low-glycemic index diet
Number of subjects: 45

Group type: COMPARATOR
Intervention: high-carbohydrate/high-fiber/low-glycemic index diet plus physical activity program
Number of subjects: 45
Study: 20726734

Group type: EXPERIMENTAL
Intervention: Individual coaching (by e‐mail, post, telephone or face‐to‐face) and a behaviour change website
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Behaviour change website
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Total duration of interventions by e‐mail
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Consulting the physical activity feedback
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Surfing depth
Number of subjects: 208
Study: 18770021

Group type: EXPERIMENTAL
Intervention: Internet delivered HIV risk reduction program
Number of subjects: 475
Study: 12065968

Group type: EXPERIMENTAL
Intervention: Aqueous solution of powdered sweetener (Zero Cal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.5% lactose solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1.5% sucrose solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 12
Study: 9726444

Group type: EXPERIMENTAL
Intervention: rG‐CSF 5 microg/kg for 5 consecutive days starting 7 days before chemotherapy with etoposide and cisplatin.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Historical group (CALGB 9132) with etoposide/cisplatin + rG‐CSF.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Course 2 results after chemotherapy.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both studies (present and historical) regarding ANC recovery.
Number of subjects: 12
Study: 7974076

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Erythromycin (500 mg 4 times daily for 7 days)
Number of subjects: 127
Study: 2566827

Group type: EXPERIMENTAL
Intervention: haem arginate 3 mg/kg per 24 h for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: haem arginate
Number of subjects: 12
Study: 31948466

Group type: EXPERIMENTAL
Intervention: EPA + DHA (1.87 g/day of EPA + 1.0 g/day of DHA)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 31127076

Group type: EXPERIMENTAL
Intervention: Cognitive Treatment (CT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Physical Treatment (PT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control Group (CTRL)
Number of subjects: 87
Study: 29084499

Group type: EXPERIMENTAL
Intervention: Goal-directed algorithm based on thromboelastometry (TEM) results during bleeding episodes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard care including conventional laboratory coagulation tests
Number of subjects: 16
Study: 26323938

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Control (guideline-based medical treatment alone)
Number of subjects: 1325
Study: 23850804

Group type: EXPERIMENTAL
Intervention: Localized t(14;18)-positive follicular lymphoma
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Disseminated t(14;18)-positive follicular lymphoma
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Nodal marginal zone lymphoma
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: t(14;18)-negative follicular lymphoma
Number of subjects: 56
Study: 20936314

Group type: EXPERIMENTAL
Intervention: Toothpaste with Scutellaria baicalensis extract (SB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo toothpaste (PLA)
Number of subjects: 40
Study: 19809295

Group type: EXPERIMENTAL
Intervention: Full prediction model (0-22 points)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Reduced prediction model (0-7 points)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Postoperative ARF occurrence
Number of subjects: 569
Study: 16399265

Group type: EXPERIMENTAL
Intervention: Quantity-comparison task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative-order judgment task
Number of subjects: 0
Study: 15514193

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) performed <2 weeks after nondisabling stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study: 11238576

Group type: EXPERIMENTAL
Intervention: Self rated health (poor to good)
Number of subjects: 21302

Group type: EXPERIMENTAL
Intervention: Self rated health (adjusted for medical history, cardiovascular risk factors, and education)
Number of subjects: 21302

Group type: EXPERIMENTAL
Intervention: Self rated health
Number of subjects: 21302
Study: 9438480

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg BD for 8 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 8 weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 4 weeks followed by FPANS 200 microg BD for 4 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo administered twice daily for 8 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo OD for 8 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo OD for 4 weeks followed by placebo BD for 4 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo BD for 8 weeks
Number of subjects: 65
Study: 8497284

Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin (600 mg for 28 days)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 31783245

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Non-adherent participants
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Varenicline adherence
Number of subjects: 89
Study: 30891999

Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure ventilation in addition to conventional treatment
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional treatment including continuous oxygen inhalation, anti-infection, bronchodilation, phlegm resolving, nutrition support, analgesia, cardiac function maintenance, coronary dilatation, anticoagulation
Number of subjects: 216
Study: 28430829

Group type: EXPERIMENTAL
Intervention: Displaying Medicare allowable fees for inpatient laboratory tests
Number of subjects: 98529
Study: 25631295

Group type: EXPERIMENTAL
Intervention: Caterpillar cereal
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 175
Study: 23070062

Group type: EXPERIMENTAL
Intervention: Living Well intervention (13-session peer-cofacilitated program)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Living Well intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study: 21224868

Group type: EXPERIMENTAL
Intervention: Daily dose of 7.5 μg of vitamin D₃ for 12 months, increasing to 22.5 μg for the remaining 18 months through fortified dairy products and nutrition and lifestyle counselling sessions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 66
Study: 19042080

Group type: EXPERIMENTAL
Intervention: ZD4054 10 mg
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ZD4054 15 mg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 16453185

Group type: EXPERIMENTAL
Intervention: Nipradilol 0.25% twice daily for 3 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Carteolol 2% twice daily for 3 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Change to carteolol after nipradilol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Change to nipradilol after carteolol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of additional IOP reduction
Number of subjects: 50
Study: 15246467

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (APDs) + Antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atypical antipsychotics (APDs)
Number of subjects: 0
Study: 11726261

Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (LCLT) 3 g/day for 3 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P) for 3 weeks
Number of subjects: 10
Study: 9230328

Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (group 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ibuprofen (group 2)
Number of subjects: 110
Study: 8390548

Group type: EXPERIMENTAL
Intervention: Trivalent vaccine containing 10(4) TCID50 of B
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Monovalent B vaccine of the same dose (10(4) TCID50)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Trivalent vaccine containing 10(6) TCID50 of B
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3102348

Group type: EXPERIMENTAL
Intervention: Penicillin (4.8 MIU aqueous procaine penicillin G plus 1 g oral probenecid)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Tetracycline (1.5 g followed by 500 mg four times daily for four days)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Non-PPNG isolates susceptibility testing
Number of subjects: 540

Group type: COMPARATOR
Intervention: Characterization of 226 non-PPNG isolates for plasmid content and auxotype
Number of subjects: 540
Study: 28859868

Group type: EXPERIMENTAL
Intervention: 20% human albumin solution (HAS) infusion
Number of subjects: 45
Study: 27128197

Group type: EXPERIMENTAL
Intervention: Pecan vicilin
Number of subjects: 25
Study: 24253834

Group type: EXPERIMENTAL
Intervention: FiO2 0.28
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FiO2 0.50
Number of subjects: 28
Study: 22484118

Group type: EXPERIMENTAL
Intervention: 5-day concomitant therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, tinidazole 500 mg twice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10-day sequential therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily for 5 days followed by esomeprazole 40 mg twice daily, levofloxacin 500 mg twice daily, tinidazole 500 mg twice daily for 5 more days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5-day concomitant therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10-day sequential therapy
Number of subjects: 90
Study: 20025055

Group type: EXPERIMENTAL
Intervention: AAE581 (balicatib) at 0, 5, 10, 25, or 50 mg/D during 1 year
Number of subjects: 675

Group type: COMPARATOR
Intervention: Control osteoporotic patients
Number of subjects: 675
Study: 17721910

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural body image therapy (BIT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 17
Study: 16446313

Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II receptor blocker) for 4 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15061232

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips
Number of subjects: 57

Group type: COMPARATOR
Intervention: Tray-based 10% carbamide peroxide/dentifrice/mouth rinse combination system
Number of subjects: 57
Study: 11326145

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (3 g intravenous infusion)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Saline infusion (100 ml x 0.9% saline, placebo)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (6 controls, mean age 55 +/- 3 years)
Number of subjects: 31
Study: 8840615

Group type: EXPERIMENTAL
Intervention: Regimen B (omeprazole 20 mg OD, bismuth subcitrate, amoxycillin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Regimen A (bismuth subcitrate 120 mg QID, amoxycillin 500 mg QID, metronidazole 400 mg TID for 2 weeks)
Number of subjects: 62
Study: 1623756

Group type: EXPERIMENTAL
Intervention: Optimal Treatment (OT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal Treatment (NT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal Treatment (NT) less than 4.5 L/min/m2
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Optimal Treatment (OT) greater than 4.5 L/min/m2
Number of subjects: 51
Study: 6595350

Group type: COMPARATOR
Intervention: Intrathecal (IT) methotrexate plus 2,400 rad cranial irradiation (C)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) methotrexate alone
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) methotrexate plus intravenous intermediate dose methotrexate
Number of subjects: 104
Study: 30298556

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg oral capsule once daily before bedtime for 2 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (matching capsules)
Number of subjects: 74
Study: 29634604

Group type: EXPERIMENTAL
Intervention: Frontal nerve block
Number of subjects: 33

Group type: COMPARATOR
Intervention: Subconjunctival injection
Number of subjects: 33
Study: 27809791

Group type: EXPERIMENTAL
Intervention: web-based health game targeting multiple cognitive domains
Number of subjects: 222

Group type: COMPARATOR
Intervention: waiting list (control group)
Number of subjects: 222
Study: 24962875

Group type: EXPERIMENTAL
Intervention: Synbiotic (1 billion CFU of Lactobacillus casei, L. rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, L. acidophilus, B. infantis, L. bulgaricus and fructooligosacharide)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 50
Study: 22823334

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PAN‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clearfil SA (CSA‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rely X Unicem (RXU‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (PAN‐2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clearfil SA (CSA‐2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rely X Unicem (RXU‐2)
Number of subjects: 72
Study: 21186921

Group type: EXPERIMENTAL
Intervention: Silver acetate solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Deionized water (placebo)
Number of subjects: 20
Study: 17420902

Group type: EXPERIMENTAL
Intervention: rHuEpo (400 U/kg, subcutaneously twice a week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: rHuEpo (800 U/kg/week)
Number of subjects: 34
Study: 16787959

Group type: EXPERIMENTAL
Intervention: Dodecanedioic acid (C-12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water load
Number of subjects: 0
Study: 12909068

Group type: EXPERIMENTAL
Intervention: Early angiography without tirofiban pre‐treatment
Number of subjects: 220

Group type: COMPARATOR
Intervention: Delayed angiography after 24‐48h pre‐treatment with tirofiban
Number of subjects: 220
Study: 10470637

Group type: EXPERIMENTAL
Intervention: Lightwand bent at 20 degrees
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Lightwand bent at 80 degrees
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Lightwand with ‐0.5 cm and 0 cm extrusion
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Lightwand with extrusion > or = 3 cm
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Lightwand bent at 40 degrees to 60 degrees with extrusion of 1 to 2 cm
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Lightwand for obese patients with body weight > or = 120% of the standard
Number of subjects: 270
Study: 8807065

Group type: EXPERIMENTAL
Intervention: E. coli isolates resistant to ampicillin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E. coli isolates resistant to trimethoprim
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: E. coli isolates resistant to tetracycline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simultaneous resistance to more than one antibiotic by E. coli isolates
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Persistent fecal shedding of resistant E. coli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Colonization by E. coli resistant to chloramphenicol, gentamicin, nitrofurantoin, or norfloxacin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Colonization by Klebsiella species and Shigella species resistant to antibiotics
Number of subjects: 20
Study: 1863002

Group type: EXPERIMENTAL
Intervention: Three-way system including hydrophilic polymer-coated catheter, daily catheter care, and disinfection with povidone-iodine
Number of subjects: 606

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 606
Study: 6821866

Group type: EXPERIMENTAL
Intervention: Surgical excision or biopsy followed by local radiotherapy and randomization to chemotherapy regimens (protocol IESS 7299)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Complete surgical excision of the primary lesion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Partial excision or biopsy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Protocol IESS 7450 (radiotherapy to all areas of known disease and four drug chemotherapy)
Number of subjects: 36
Study: 31927509

Group type: EXPERIMENTAL
Intervention: Enhancing Trauma Awareness course
Number of subjects: 100
Study: 31539335

Group type: COMPARATOR
Intervention: Traditional approach (ad hoc, rigid suction catheter airway decontamination)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Intentional esophageal intubation (IEI)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Suction-assisted laryngoscopy and airway decontamination (SALAD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional approach
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 31
Study: 27368672

Group type: EXPERIMENTAL
Intervention: Single-dose tenapanor 180 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Repeated-dose tenapanor 15, 30, 60, or 90 mg twice daily for 7 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26318355

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 502

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 502
Study: 27128839

Group type: COMPARATOR
Intervention: Crushed rivaroxaban tablet in applesauce suspension (Crushed‐Oral)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Crushed rivaroxaban tablet in water suspension via NG tube (Crushed‐NG)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Whole rivaroxaban tablet (Reference [Whole‐Oral])
Number of subjects: 55
Study: 23094903

Group type: EXPERIMENTAL
Intervention: Euglycemic control (80‐140 mg/dL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional approach (180‐200 mg/dL)
Number of subjects: 40
Study: 19713801

Group type: EXPERIMENTAL
Intervention: Music therapy for 30 minutes on 3 consecutive days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (30-minute rest on 3 consecutive days)
Number of subjects: 120
Study: 17240225

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (n = 74)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (n = 79)
Number of subjects: 153
Study: 15038639

Group type: EXPERIMENTAL
Intervention: Virtual reality simulator training (6-10 hours)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional preclinical dentistry laboratory training
Number of subjects: 68
Study: 11346860

Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9165384

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 144
Study: 8196433

Group type: EXPERIMENTAL
Intervention: Intraoperative anesthesia of the ilioinguinal and iliohypogastric nerves with a long-acting local anesthetic combined with a vasoconstrictor
Number of subjects: 150000

Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was)
Number of subjects: 150000
Study: 3467505

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dye laser iridotomy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Surgical peripheral iridectomy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 29
Study: 30095360

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (St. Thomas' Harefield preparation)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia at 4-6°C
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Topical cooling
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Induction and maintenance dosing
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Re-dosing interval
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Willingness to participate in a trial
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia
Number of subjects: 44